Can-Fite Announces Final Data Analysis from Phase II NASH Study: Highly Significant and Sustained Reduction in Liver Fat Volume Throughout Study Period
Stock Information for Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Loading
Please wait while we load your information from QuoteMedia.